Johnson & Johnson vs Repligen Corp
JNJ vs RGEN — side-by-side comparison from reported financials. JNJ leads 9, RGEN leads 1 of 10 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Repligen Corp
RGEN · Healthcare
$173.88+6.13%Mixed
| Metric | JNJ | RGEN |
|---|---|---|
| Price | $261.79 | $173.88 |
| Market cap | $631B | $11.0B |
| Revenue (TTM) | $97.9B | $785M |
| Revenue growth | +5.6% | -2.7% |
| Net margin | 21.5% | 5.3% |
| Free cash flow | $22.2B | $112M |
| Net cash (debt) | ($27.8B) | $225M |
| 1-year price return | +37.0% | +16.8% |
| P/E | 29.9 | 265.8 |
| P/E vs own history (cheap-side %) | 16% | 2% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 2% |
| CV checks passed | 10 of 11 | 7 of 11 |
| Employees | 140,800 | 2,000 |
Full résumé-style profiles: JNJ CV · RGEN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.